With respect to anti-EGFR therapy efficacy for pretreated mCRC patients, Brule í et al.,reanalyzed the results of NCIC CO.17 trial (cetuximab vs best supportive care) according to primary tumor site. The gene discussed is EGFR; the disease is neoplasm.